Long-term safety and efficacy of subcutaneous efgartigimod PH20: Interim results of the ADAPT-SC+ trial

Authors
Category Primary study
Conference10th Congress of the European Academy of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: 61a8786159f4e5883ae57f4aeecbbea09fbf6ef2
First added on: Jan 07, 2026